In 2007, the United States (U.S.) market for osteoporosis management products totaled approximately $7.6 billion.
Sales of these products are expected to increase at a compound annual rate of 6.6%, reaching an estimated $9.3
billion in the year 2010.
This new report from Medtech Insight includes analyses of products, technologies, current and forecast markets,
competitors, and opportunities in the U.S. osteoporosis management products market. According to the first-ever
U.S. Surgeon General's report on the nation's bone health, by the year 2020 one out of two Americans over the age of
50 will be at risk for fractures from osteoporosis. Currently, approximately 10 million people in the U.S. are estimated
to have osteoporosis, and another 34 million are believed to have low bone mass, placing them at risk for developing
Products for the diagnosis and treatment of osteoporosis that are covered in this report include biochemical markers,
bone densitometry systems, and hormone replacement and osteoporosis drugs. These include antiresorptive drugs
such as bisphosphonates, calcitonins, estrogen, and selective estrogen receptor modulators; bone-forming drugs such
as parathyroid hormone and sodium fluoride; combination drugs; and treatments such as cathepsin K inhibitors, gene
therapy, monoclonal antibodies, selective androgen receptor modulators, and statin drugs.
TABLE OF CONTENTS:
i. Osteoporosis Incidence and Prevalence
ii. Osteoporosis Diagnosis and Management
a. Bone Densitometry
b. Biochemical Markers
c. Osteoporosis Treatments
iii. Market Analysis
a. Bone Densitometry Systems
b. Biochemical Markers
c. Hormone Replacement Therapy and Osteoporosis Drugs
i. Hormone Replacement Therapy Drugs
ii. Osteoporosis Drugs
Exhibit ES-1: 2007, Osteoporosis-Caused Fracture Incidence, by Site
Exhibit ES-2: Osteoporosis Management Products, Combined Market Forecast, 2005-2010
Exhibit ES-3: Total Bone Densitometry Systems, Market Forecast, 2005-2010
Exhibit ES-4: Bone Remodeling Biochemical Marker Tests, Market Forecast, 2005-2010
Exhibit ES-5: 2007, Hormone Replacement Therapy and Osteoporosis Drugs, Sales by Product Category
Exhibit ES-6: Hormone Replacement Therapy Drugs, Market Forecast, 2005-2010
Exhibit ES-7: Osteoporosis Drugs, Market Forecast, 2005-2010
Exhibit ES-8: Hormone Replacement Therapy and Osteoporosis Drugs, Market Forecast, 2005-2010
1. OSTEOPOROSIS MANAGEMENT PRODUCTS MARKET
1.1 Overview of Osteoporosis
1.1.1 Incidence, Prevalence, and Cost
1.1.2 Types of Osteoporosis
1.1.3 Risk Factors
1.2.1 Bone Densitometry
220.127.116.11 Products, by Application
18.104.22.168.1 Hospital-Based Densitometry Systems
22.214.171.124.2 Office-Based Densitometry Systems
126.96.36.199.3 Software-Based Systems
188.8.131.52 Products and Suppliers
184.108.40.206.1 CooperSurgical/The Cooper Companies
220.127.116.11.2 GE Healthcare/General Electric Company
18.104.22.168 Market Analysis
22.214.171.124 Competitive Analysis
1.2.2 Biochemical Markers
126.96.36.199 Products and Suppliers
188.8.131.52.1 Beckman Coulter
184.108.40.206.2 Roche Diagnostics/F. Hoffmann- La Roche/Roche Holding
220.127.116.11.3 Inverness Medical Innovations
18.104.22.168.4 Orion Diagnostica Oy/Orion Group
22.214.171.124 Market Analysis
126.96.36.199 Competitive Analysis
1.3.1 Antiresorptive Drugs
188.8.131.52 Selective Estrogen Receptor Modulators
1.3.2 Bone-Forming Drugs
184.108.40.206 Sodium Fluoride
220.127.116.11 Parathyroid Hormone
1.3.3 Dual-Acting Drug
1.3.4 Other Treatments
18.104.22.168 Monoclonal Antibodies
22.214.171.124 Cathepsin K Inhibitors
126.96.36.199 Gene Therapy
188.8.131.52 Statin Drugs
184.108.40.206 Selective Androgen Receptor Modulators
1.3.5 Market Analysis
220.127.116.11 Hormone Replacement Therapy Drugs
18.104.22.168 Osteoporosis Drugs
1.3.6 Competitive Analysis
1.3.7 Combined Market Analysis
Exhibit 1-1: 2007, Osteoporosis-Caused Fracture Incidence, by Site
Exhibit 1-2: Prevalence of Osteoporosis and Low Bone Mass in Men and Women Age 50 and Older, by Ethnicity
Exhibit 1-3: Types of Osteoporosis
Exhibit 1-4: Leading Risk Factors for Osteoporosis
Exhibit 1-5: Comparison of Bone Densitometry and Osteoporosis Biochemical Marker Screenings
Exhibit 1-6: Imaging Technologies Used to Diagnose Osteoporosis
Exhibit 1-7: 2008, Selected Bone Densitometry Systems
Exhibit 1-8: Bone Densitometry Hospital Systems, Market Forecast, 2005-2010
Exhibit 1-9: Bone Densitometry Office Systems, Market Forecast, 2005-2010
Exhibit 1-10: Total Bone Densitometry Systems, Market Forecast, 2005-2010
Exhibit 1-11: 2007, Bone Densitometry Systems Market, Share by Supplier
Exhibit 1-12: Comparison of Bone Remodeling Biochemical Markers
Exhibit 1-13: 2008, Selected Bone Remodeling Biochemical Marker Tests
Exhibit 1-14: Bone Remodeling Biochemical Marker Tests, Market Forecast, 2005-2010
Exhibit 1-15: 2007, Bone Remodeling Biochemical Marker Tests Market, Share by Supplier
Exhibit 1-16: 2008, Selected Current and Emerging Pharmaceutical Treatments for Osteoporosis
Exhibit 1-17: Hormone Replacement Therapy and Osteoporosis Drugs, Market Forecast, 2005-2010
Exhibit 1-18: 2007, Hormone Replacement Therapy and Osteoporosis Drugs, Sales by Product Category
Exhibit 1-19: Hormone Replacement Therapy Drugs, Market Forecast, 2005-2010
Exhibit 1-20: Osteoporosis Drugs, Market Forecast, 2005-2010
Exhibit 1-21: 2007, Hormone Replacement Therapy and Osteoporosis Drugs Market, Share by Supplier
Exhibit 1-22: Osteoporosis Management Products, Combined Market Forecast, 2005-2010
2. COMPANY PROFILES
2.1 The Cooper Companies, Inc.
2.2 General Electric Company
2.3 Hologic, Inc.
2.4 Inverness Medical Innovations, Inc.
2.5 Eli Lilly and Company
2.6 Merck & Company, Inc.
2.7 Novartis AG
2.8 Procter & Gamble Company
2.9 Quidel Corporation
2.10 Roche Holding AG
APPENDIX: COMPANY LISTING
Abbott Laboratories, Inc.
Beckman Coulter, Inc.
Novartis Vaccines and Diagnostics, Inc.
CooperSurgical, Inc./ The Cooper Companies, Inc.
Eli Lilly and Company
Emisphere Technologies, Inc.
FUJIFILM Medical Systems USA, Inc./FUJIFILM Corporation
GE Healthcare/ General Electric Company
F. Hofmann-La Roche LTD/ Roche Holding LTD
Human Genome Sciences, Inc.
Inverness Medical Innovations, Inc.
Ligand Pharmaceuticals, Inc.
Lone Oak Medical Technologies LLC
Merck & Company, Inc.
Nastech Pharmaceutical Company, Inc.
Noven Pharmaceuticals, Inc.
NPS Pharmaceuticals, Inc.
Nycomed International Management GmbH
Orion Diagnostica Oy/ Orion Corporation
Oscient Pharmaceuticals Corporation
Procter & Gamble Company
ProStrakan Group PLC
Roche Diagnostics Corporation/ F. Hoffmann-La Roche LTD/ Roche Holding LTD
Takeda Pharmaceutical Company LTD
TAP Pharmaceutical Products, Inc.
Unigene Laboratories, Inc.
Upsher-Smith Laboratories, Inc.
Warner Chilcott LTD
Need help finding medtech research? Let us help you!